Our resource hub is home to a wealth of articles, stories and videos about managing and living with type 1 diabetes.
Place your order for our free information packs that support adults and children who have been recently diagnosed.
Our researchers are working on different ways to develop a cure for type 1 diabetes - from growing insulin-producing beta cells in labs to hacking the immune system.
Learn about the technologies that can deliver insulin automatically when needed. And discover the next generation of insulins that are currently being developed.
You could win a cash prize of up to £25,000 when you play the JDRF lottery. As well as the chance to win great prizes, you’ll also help fund our research to find a cure for type 1 diabetes.
Your donations help support people living with type 1 diabetes today and fund the best treatment and cure research, no matter where in the world it takes place.
The announcement is the biggest treatment breakthrough for type 1 diabetes since the discovery of insulin.
The focus of this event is ‘type 1 technology’ covering aspects such as access, choice, and everyday living with type 1 technology.
We provide a wealth of information and free resources to help you support and empower your patients or students.
Take our free course for schools to learn more about supporting pupils with type 1 diabetes in educational settings.
Home > News & Events > News
The award recognises Professor Dayan’s remarkable accomplishments in type 1 diabetes research.
Two siblings who have unique changes in a key gene have given researchers new insights that could help lead to innovative new treatments in type 1 diabetes.
JDRF-funded researchers from the University of Birmingham have joined forces with NHS England to develop a diagnostic code for use on electronic medical records of people in the earliest stages of type 1 diabetes, allowing them to receive better, more timely healthcare and access to emerging treatments.
JDRF and Digibete have teamed up to create Coping with Diabetes, a new interactive support tool to help children and young people with type 1 look after their mental health and wellbeing.
A new test by Randox, developed with JDRF-funded researchers at the University of Exeter, is the first in the world to use genetics to quickly identify who is at high risk of developing type 1 diabetes.
A transplant of stem cells grown into pancreatic islets has allowed a primate with type 1 to make its own insulin again.
Diabetes is the leading cause of kidney disease in the UK, so we've joined forces with Diabetes UK, and Kidney Research UK to identify the research gaps and care needs in the field.
JDRF and the Helmsley Charitable Trust have announced over £1.5 million in joint funding for five international researchers – including one UK-based researcher – to access unique data sources and unravel how type 1 diabetes develops, with the goal of preventing the condition.
We wrote to the producers of the hit BBC show after they broadcast jokes about type 1 diabetes.
Researchers have developed a new oral insulin that travels in an inactive state to the liver and is only activated by rising blood glucose levels.
Parliamentary Inquiry chaired by our Global Health Ambassador, Rt. Hon Theresa May MP and Sir George Howarth MP, highlights the risks of type 1 diabetes-related eating disorders (T1DE).
We could be one step closer to replacing the need for regular insulin injections in people living with type 1 diabetes, thanks to JDRF-funded research in Australia published this week in the Nature journal.
Last night JDRF teamed up with the Royal Osteoporosis Society to host a charity carol concert at St Paul’s Cathedral. The event featured a lineup of familiar faces, including The Rt. Hon Theresa May MP and Derrick Evans MBE.
In an historic advancement in the treatment of type 1 diabetes, the National Institute for Health and Care Excellence (NICE) today approves hybrid closed loop for the majority of people living with type 1 diabetes in England and Wales.
EDENT1FI aims to develop a population screening programme for type 1, revolutionising how the condition is diagnosed and managed.
It's been an incredible year for advancements in type 1 diabetes research and treatments. We take a look at the progress we made in 2023, funded by you, our supporters.
We support the introduction of dedicated sex and gender policies in UK research, which will encourage scientists to think about sex and/or gender in their research.
The newest member of our innovative autoimmune research initiative, Connect Immune Research, is Juvenile Arthritis Research.
World-first clinical trial finds drug can suppress progression of type 1 diabetes in people newly diagnosed
The research, which was co-funded by JDRF, reveals that drugs that target the immune system offer very effective and rapid improvements in stabilising blood sugar levels, often within just three months.
The new JDRF-funded clinical trial called SOPHIST will test a drug to help people with type 1 diabetes and heart failure.
Results from a clinical trial called the PROTECT study show that teplizumab can preserve beta cell function in children and adolescents newly diagnosed with type 1 diabetes.
Children in Northern Ireland are now eligible for a trial screening programme that will identify those at high risk of developing type 1 diabetes in the future.
Thanks to JDRF supporters, we’ve been able to award a £1.3 million grant to King’s College London (KCL) and Steno Diabetes Center Copenhagen to examine how existing drugs, known as SGLT inhibitors, could delay the progression of kidney disease in people living with type 1 diabetes.
A JDRF-supported trial published in the New England Journal of Medicine and presented at the European Association for the Study of Diabetes conference has shown that hybrid closed loop technology helps pregnant women better manage their blood sugars compared to traditional insulin pumps or multiple daily injections.
A clinical trial funded by JDRF suggests that treating children with antiviral drugs when they are first diagnosed with type 1 diabetes could preserve their ability to produce some insulin.
Professor Roman Hovorka, who JDRF has funded since 2006 to develop hybrid closed loop (HCL) technology, has won this year’s EASD-Novo Nordisk Foundation Diabetes Prize for Excellence.
We’ve written a letter to Gillian Keegan MP, Secretary of State for Education, asking her to make exemptions to the Government’s policy on banning mobile phones in schools. We thought you might like to read it.
Our survey has shown that half of people with type 1 diabetes feel that the condition holds them back from physical activity and exercise.
As part of its assessment of hybrid closed loop (HCL), the National Institute for Health and Care Excellence (NICE) has today published an additional consultation on its roll out.
In a JDRF-funded research project in Australia, scientists have turned human pancreatic ductal cells into insulin-producing cells, offering promise for restoring the ability to make insulin in people living with type 1 diabetes.
We have today welcomed our President, Her Majesty The Queen, to University College London (UCL) Institute of Immunity and Transplantation.
Insulet, the company who make Omnipod® products, has announced that their Omnipod® 5 hybrid closed loop (HCL) technology is now available in the UK.
In a study co-funded by JDRF and Diabetes UK, researchers identified 13 genes involved in immune responses, which are activated specifically in people who develop type 1 diabetes at a young age.
We’re pleased to announce the appointment of two new Board Directors, Nadia Swann and Sarah Johnson.
Don’t miss out on the latest research, inspiring stories, tech news, upcoming events, and handy information on living well with type 1. Join us now and receive it all straight to your inbox.
Our research is improving the lives of people with type 1 and making strides towards a cure. We’ll keep pushing until we make type 1 diabetes a thing of the past.